Wanling Xie1, Sarah Drouin2,3, Mari Nakabayashi2, Mark Pomerantz2, Gwo-Shu Mary Lee2, Philip W Kantoff2,4, Nima Sharifi5. 1. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. 2. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. 3. Interne de Paris, Urology, Paris, France. 4. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Cancer Biology, Cleveland Clinic, Cleveland, Ohio.
Abstract
BACKGROUND: Silencing SOD2 expression upregulates androgen receptor (AR) signaling and expression of SOD2 is downregulated in CRPC, compared with untreated tumors. The decreased SOD2 activity could lead to AR gain-of-function and the development of castration-resistance. METHODS: We genotyped SOD2-rs4880 in a cohort of 753 prostate cancer patients receiving androgen deprivation therapy (ADT) between 1996 and 2010. The rs4880 encodes Ala16Val in SOD2 and the Val variant has been demonstrated to be functionally less efficient than the Ala variant. We assessed the impact of SOD2-rs4880 variants on the time to progression (TTP) and overall survival (OS) on ADT using multivariable Cox regression. RESULTS: Four hundred thirty-two out of 753 (57%) had metastases at the time of ADT initiation. Overall, median TTP on ADT was 18.4 (95%CI: 15.8, 20.9) months and median overall survival (OS) from ADT initiation was 6.3 (95%CI: 5.8, 6.8) years. In unadjusted and adjusted analyses, there was no association between SOD-rs4880 and TTP or OS on ADT (P > 0.05). Results were similarly negative among patients with and without metastatic disease at ADT initiation. CONCLUSIONS: Our result suggests that a functional genetic variant in SOD2 does not determine the efficacy of ADT for prostate cancer. It is possible that the drastic downregulation of SOD2 in advanced prostate cancer cells may have overridden any influence of the genetic variation of SOD2. This study suggests the need for careful consideration about timing if the application of SOD2 mimetics for prostate cancer therapy is considered. Prostate 76:1338-1341, 2016.
BACKGROUND: Silencing SOD2 expression upregulates androgen receptor (AR) signaling and expression of SOD2 is downregulated in CRPC, compared with untreated tumors. The decreased SOD2 activity could lead to AR gain-of-function and the development of castration-resistance. METHODS: We genotyped SOD2-rs4880 in a cohort of 753 prostate cancerpatients receiving androgen deprivation therapy (ADT) between 1996 and 2010. The rs4880 encodes Ala16Val in SOD2 and the Val variant has been demonstrated to be functionally less efficient than the Ala variant. We assessed the impact of SOD2-rs4880 variants on the time to progression (TTP) and overall survival (OS) on ADT using multivariable Cox regression. RESULTS: Four hundred thirty-two out of 753 (57%) had metastases at the time of ADT initiation. Overall, median TTP on ADT was 18.4 (95%CI: 15.8, 20.9) months and median overall survival (OS) from ADT initiation was 6.3 (95%CI: 5.8, 6.8) years. In unadjusted and adjusted analyses, there was no association between SOD-rs4880 and TTP or OS on ADT (P > 0.05). Results were similarly negative among patients with and without metastatic disease at ADT initiation. CONCLUSIONS: Our result suggests that a functional genetic variant in SOD2 does not determine the efficacy of ADT for prostate cancer. It is possible that the drastic downregulation of SOD2 in advanced prostate cancer cells may have overridden any influence of the genetic variation of SOD2. This study suggests the need for careful consideration about timing if the application of SOD2 mimetics for prostate cancer therapy is considered. Prostate 76:1338-1341, 2016.
Authors: Carolyn J M Best; John W Gillespie; Yajun Yi; Gadisetti V R Chandramouli; Mark A Perlmutter; Yvonne Gathright; Heidi S Erickson; Lauren Georgevich; Michael A Tangrea; Paul H Duray; Sergio González; Alfredo Velasco; W Marston Linehan; Robert J Matusik; Douglas K Price; William D Figg; Michael R Emmert-Buck; Rodrigo F Chuaqui Journal: Clin Cancer Res Date: 2005-10-01 Impact factor: 12.531
Authors: Haojie Li; Philip W Kantoff; Edward Giovannucci; Michael F Leitzmann; J Michael Gaziano; Meir J Stampfer; Jing Ma Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701
Authors: Lauren C Harshman; Xiaodong Wang; Mari Nakabayashi; Wanling Xie; Loana Valenca; Lillian Werner; Yongjiang Yu; Aaron M Kantoff; Christopher J Sweeney; Lorelei A Mucci; Mark Pomerantz; Gwo-Shu Mary Lee; Philip W Kantoff Journal: JAMA Oncol Date: 2015-07 Impact factor: 31.777
Authors: S Shimoda-Matsubayashi; H Matsumine; T Kobayashi; Y Nakagawa-Hattori; Y Shimizu; Y Mizuno Journal: Biochem Biophys Res Commun Date: 1996-09-13 Impact factor: 3.575
Authors: Robert W Ross; Wanling Xie; Meredith M Regan; Mark Pomerantz; Mari Nakabayashi; Timothy J Daskivich; Oliver Sartor; Mary-Ellen Taplin; Philip W Kantoff; William K Oh Journal: Cancer Date: 2008-03-15 Impact factor: 6.860
Authors: June M Chan; William K Oh; Wanling Xie; Meredith M Regan; Meir J Stampfer; Irena B King; Miyako Abe; Philip W Kantoff Journal: J Clin Oncol Date: 2009-06-15 Impact factor: 44.544